rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

RenovoRx, Inc.

RNXT · Nasdaq

Health CareBiotechnologyJust started moving

RNXT stood above a rising 150-day average in 12 of the last 52 weekly readings, including each of the last 11 weeks. It is 0.4% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
11 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$123K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
29 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$115KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months13
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Mark VollChief Financial Officerbought25,000at $0.787619 May 2026filed 21 May 2026
Mark VollChief Financial Officerbought97,20020 Mar 2026filed 24 Mar 2026
Mark VollChief Financial Officerbought48,60020 Mar 2026filed 24 Mar 2026
Shaun BagaiChief Executive Officerbought24,30020 Mar 2026filed 24 Mar 2026
Shaun BagaiChief Executive Officerbought12,15020 Mar 2026filed 24 Mar 2026
Laurence MartonDirectorbought9,72020 Mar 2026filed 24 Mar 2026
Laurence MartonDirectorbought4,86020 Mar 2026filed 24 Mar 2026
Ramtin AgahChief Medical Officerbought10,000at $0.997521 Jan 2026filed 22 Jan 2026
Ramtin AgahChief Medical Officerbought9,795at $0.8631 Dec 2025filed 5 Jan 2026
Ramtin AgahChief Medical Officerbought205at $0.82630 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders29-1 on the quarter
New · exited4 · 5
Reported value$9.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
AIGH Capital Management LLCadded · filed 7 Aug 20264,405,439$4.3M+699,242+18.9%
Bleichroeder LPunchanged · filed 13 Aug 20261,666,098$1.6M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,443,742$1.4M-3,435−0.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026424,148$416K+42,425+11.1%
Wealthspire Advisors, LLCunchanged · filed 11 Aug 2026252,525$247K00.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026240,330$236K+82,428+52.2%
CITADEL ADVISORS LLCreduced · filed 14 Aug 2026133,597$131K-99,087−42.6%
Chicago Partners Investment Group LLCunchanged · filed 30 Jul 202692,356$79K00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 202685,207$84K+43,046+102.1%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT COreduced · filed 12 Aug 202674,596$73K-24,864−25.0%
31 Mar 2023 – 30 Jun 2026
102029Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

K. Angela Macfarlane Company insiderDirector · last 1 Oct 20261 · 0
Laurence Marton Company insiderDirector · last 1 Oct 20263 · 0
Robert J. Spiegel Company insiderDirector · last 1 Oct 20261 · 0
Una S. Ryan Company insiderDirector · last 1 Oct 20260 · 0
Mark Voll Company insiderChief Financial Officer · last 10 Sep 20262 · 0
Leesa Gentry Company insiderChief Clinical Officer · last 3 Apr 20260 · 0
Ramtin Agah Company insiderChief Medical Officer · last 3 Apr 202614 · 0
Shaun Bagai Company insiderChief Executive Officer · last 3 Apr 202610 · 0
Ron Kocak Company insiderVP, Controller and PAO · last 1 Jul 20253 · 0
Angela Nelms Company insiderChief Operating Officer · last 19 Jan 20241 · 0
David Diamond Company insiderDirector · last 1 Oct 20230 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202570.9%
Free cash flow marginFY 2025 · to 31 Dec 2025-977%
Share count trendFY 2025 · to 23 Mar 202623.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.0M
Free cash flowFY 2025 · to 31 Dec 2025−$11.0M

Analyst forecasts

No analyst forecasts yet.